This is the nineteenth video in the series of COVID-19 pandemic.
This lecture comprehensively describes the pharmacologic action of the drug NARSOPLIMAB in COVID-19 patients. In COVID-19, acute respiratory distress syndrome (ARDS) and thrombotic events are frequent, life-threatening complications. Autopsies commonly show arterial thrombosis and severe endothelial damage. Endothelial damage, which can play an early and central pathogenic role in ARDS and thrombosis, activates the lectin pathway of complement. Mannan-binding lectin-associated serine protease-2 (MASP-2), the lectin pathway’s effector enzyme, binds the nucleocapsid protein of severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2), resulting in complement activation and lung injury. Narsoplimab, a fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody against MASP-2, inhibits lectin pathway activation and has anticoagulant effects. In this study, the first time a lectin-pathway inhibitor was used to treat COVID-19, six COVID-19 patients with ARDS requiring continuous positive airway pressure (CPAP) or intubation received narsoplimab under compassionate use. At baseline and during treatment, circulating endothelial cell (CEC) counts and serum levels of interleukin-6 (IL-6), interleukin-8 (IL-8), C-reactive protein (CRP) and lactate dehydrogenase (LDH) were assessed. Narsoplimab treatment was associated with rapid and sustained reduction of CEC and concurrent reduction of serum IL-6, IL-8, CRP and LDH. Narsoplimab was well tolerated; no adverse drug reactions were reported. Two control groups were used for retrospective comparison, both showing significantly higher mortality than the narsoplimab-treated group. All narsoplimab-treated patients recovered and survived. Narsoplimab may be an effective treatment for COVID-19 by reducing COVID-19-related endothelial cell damage and the resultant inflammation and thrombotic risk.
References –
1. Endothelial Injury and Thrombotic Microangiopathy in COVID-19: Treatment with the Lectin-Pathway Inhibitor Narsoplimab
2. Rationale for targeting complement in COVID‐19
Link of my Facebook Page –
COVID-19 Video Links –
1. Coronavirus (COVID-19) – Virology and Outbreak –
2. Coronavirus (COVID-19) – ACE and ARB Dilemma –
3. Coronavirus (COVID-19) – Treatment – REMDESIVIR – Hype or Real –
4. Coronavirus (COVID-19) – Treatment – Chloroquine + Azithromycin – Hype or Real Part II
5. Coronavirus (COVID 19) -Treatment/Cure – Chloroquine + Azithromycin – Hype or Real
6. Coronavirus (COVID-19) – Treatment/Cure – Tocilizumab – Hype or Real
7. Coronavirus (COVID-19) – Why Are Men More Affected Than Women? – Pathogenesis and Receptor Binding
8. Coronavirus (COVID-19) – Treatment/Cure – RNA Dependent RNA Polymerase Analysis
9. COVID-19 and Diabetes – Treatment/Cure – DPP4 Inhibitors – Hype or Real
10. COVID-19 and Ivermectin – A Scientific Approach
11. COVID-19 and ARDS – Vascular Complications
2. IL-6: from its discovery to clinical applications
12. CD 147 – An Alternative Receptor For SARS-CoV-2
13. SARS-CoV-2 and Interleukin 6 – Complications in COVID-19
14. COVID-19 and LERONLIMAB – A Scientific Perspective
15. COVID-19 and FAVIPIRAVIR/AVIGAN/AVIFAVIR – A Scientific Perspective
16. COVID-19 and DEXAMETHASONE – A Scientific Perspective
17. COVID-19 and COMPLEMENT INHIBITORS – A Scientific Perspective
18. COVID-19 and REMDESIVIR – First FDA Approved Drug Against SARS-CoV-2
